BB1 Stock Overview
Focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BlinkLab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.29 |
| 52 Week High | AU$0.41 |
| 52 Week Low | AU$0.20 |
| Beta | 0 |
| 11 Month Change | 11.32% |
| 3 Month Change | 37.21% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 11.32% |
Recent News & Updates
Shareholder Returns
| BB1 | AU Healthcare Services | AU Market | |
|---|---|---|---|
| 7D | 13.5% | 4.7% | 1.5% |
| 1Y | n/a | 122.4% | 17.2% |
Return vs Industry: Insufficient data to determine how BB1 performed against the Australian Healthcare Services industry.
Return vs Market: Insufficient data to determine how BB1 performed against the Australian Market.
Price Volatility
| BB1 volatility | |
|---|---|
| BB1 Average Weekly Movement | 14.9% |
| Healthcare Services Industry Average Movement | 8.2% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: BB1's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: BB1's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Hendrikus Boele | www.blinklab.org |
BlinkLab Limited focuses on the development and commercialization of intellectual property related to smartphone-neurobehavioral testing. The company’s smartphone-based application serves as a device for conducting neurobehavioral evaluations. Its application also enables remote and rapid testing to aid research on neurodevelopmental and neurodegenerative conditions such as schizophrenia, autism, attention deficit hyperactivity disorder (ADHD), and various forms of dementia.
BlinkLab Limited Fundamentals Summary
| BB1 fundamental statistics | |
|---|---|
| Market cap | AU$29.25m |
| Earnings (TTM) | -AU$1.75m |
| Revenue (TTM) | AU$36.96k |
791.4x
P/S Ratio-16.7x
P/E RatioIs BB1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BB1 income statement (TTM) | |
|---|---|
| Revenue | AU$36.96k |
| Cost of Revenue | AU$270.32k |
| Gross Profit | -AU$233.36k |
| Other Expenses | AU$1.52m |
| Earnings | -AU$1.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | -631.37% |
| Net Profit Margin | -4,743.57% |
| Debt/Equity Ratio | 0% |
How did BB1 perform over the long term?
See historical performance and comparison